Samsung Epis Holdings Submits 2026 Conglomerate Status Disclosure – Newly Established Holding Company with Sound Financials, Minimal Impact on Shareholder Value
Samsung Epis Holdings, established in November 2025 via a spin-off from Samsung Biologics, filed its first conglomerate status disclosure on June 1, 2026
Total assets of 3.35 trillion KRW, total liabilities of 11.9 billion KRW, and equity of 3.34 trillion KRW, resulting in a debt ratio of 0.36% with zero borrowings, indicating a very sound financial structure
As of end-2025, revenue was zero, operating loss 1.86 billion KRW, net loss 1.78 billion KRW, reflecting early operational stage
Ownership structure: Samsung C&T 43.06%, Samsung Electronics 31.22%, and other related parties 74.47% in total; treasury shares 0.19%
Wholly owns Samsung Bioepis and Epis NexLab domestically, and consolidated Samsung Bioepis (China) Co., Ltd. as an overseas subsidiary
Board consists of 3 inside directors and 3 outside directors, with audit, compensation, and ESG committees established
Key intra-group transactions include management service and property lease; trademark royalties are exempt
[AI Summary]This filing is a routine periodic report of a newly established holding company, containing no capital-raising or shareholder return events, thus limited impact on stock price. Despite early operating losses, the ultra-low leverage and strong capital base make it a stable investment.
KOSPI Filing Information
Filing: [Correction of Description] Large Business Group Status Disclosure [Annual Disclosure and for 1st Quarter (Individual Company)]